Algorithm tracks cancer type down to methy...Researchers have applied a self-learning algorithm to distinguish the almost 100 brain cancer types through their methylation pattern in a routine diagnostic setting. The method eliminates inter-pathologist … more ➔
Business as usual in AmsterdamThe tremendous success of last years BIO Europe Spring in Barcelona was hard to beat. But the follow-up this year in Amsterdam organised by EBD Group together with Health Holland crystallised … more ➔
MYR Pharma completes chronic hepatitis del...German MYR Pharma has completed a proof of concept Phase IIb trial with its first-in-class hepatitis D entry inhibitor Myrcludex B, which is developed under the European Medicines Agencys PRIME … more ➔
Sanofis alirocumab improves cardiovascul...Alirocumab, Sanofi s/Regenerons PCSK9 inhibitor, in combination with statins has met the endpoint of reducing the number of major adverse cardiovascular events (MACE) over statin monotherapy … more ➔
Medimmune finds target against systemic sc...Researchers at Medimmune, AstraZeneca’s biologics arm, have identified a mechanism that drives the autoimmune disease systemic sclerosis. more ➔
Bioprocessing challenges in the focusAbout 300 bioeconomy experts from science and business came together in Strasbourg for the first edition of BIOKET to discuss up-scaling challenges, new processing technologies as well as the potential … more ➔
Sanofi to outsource antiinfectives R&...Evotec and Sanofi want to create an Evotec-led infectious disease open innovation R&D platform at Sanofis antiinfectives hub in Lyon. Talks are expected to close in H1/2018 with an option agre … more ➔
Heidelberg Pharma inks US$334m R&D co...Under an exclusive licence option agreement, Heidelberg Pharma will develop ATACs (alpha-amanitin antibody conjugates) for Magenta Therapeutics Inc. across several targeted conditioning programmes … more ➔
Investors keen to put money into AMR SMEsInvestments into new drugs to tackle antimicrobial resistance (AMR) are set to boost the participation of SMEs. At the 11th Berlin Conference on Life Sciences, two new financing initiatives, which focus … more ➔
Santheras idebenone not efficient in PPM...Swiss Santhera Pharmaceuticals EU-approved LHON treatment Raxone (idebenone) has failed to show clinical efficacy in another indication: After US and EU regulators rejected an extension of market approval … more ➔
